Pharma Mar Sa Stock Current Valuation
| PHM Stock | EUR 75.50 0.10 0.13% |
Valuation analysis of Pharma Mar SA helps investors to measure Pharma Mar's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Undervalued
Today
Please note that Pharma Mar's price fluctuation is very steady at this time. Calculation of the real value of Pharma Mar SA is based on 3 months time horizon. Increasing Pharma Mar's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Pharma Mar is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Pharma Stock. However, Pharma Mar's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 75.5 | Real 79.73 | Hype 75.6 |
The real value of Pharma Stock, also known as its intrinsic value, is the underlying worth of Pharma Mar SA Company, which is reflected in its stock price. It is based on Pharma Mar's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Pharma Mar's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Pharma Mar SA helps investors to forecast how Pharma stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Pharma Mar more accurately as focusing exclusively on Pharma Mar's fundamentals will not take into account other important factors: Pharma Mar SA Company Current Valuation Analysis
Pharma Mar's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Pharma Mar Current Valuation | 1.07 B |
Most of Pharma Mar's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pharma Mar SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Pharma Mar SA has a Current Valuation of 1.07 B. This is 92.58% lower than that of the Healthcare sector and 77.06% lower than that of the Biotechnology industry. The current valuation for all Spain stocks is 93.59% higher than that of the company.
Pharma Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pharma Mar's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Pharma Mar could also be used in its relative valuation, which is a method of valuing Pharma Mar by comparing valuation metrics of similar companies.Pharma Mar is currently under evaluation in current valuation category among its peers.
Pharma Fundamentals
| Return On Equity | 0.47 | |||
| Return On Asset | 0.13 | |||
| Profit Margin | 0.35 % | |||
| Operating Margin | 0.33 % | |||
| Current Valuation | 1.07 B | |||
| Shares Outstanding | 18.09 M | |||
| Shares Owned By Insiders | 26.95 % | |||
| Shares Owned By Institutions | 10.48 % | |||
| Price To Earning | (38.29) X | |||
| Price To Book | 5.69 X | |||
| Price To Sales | 5.17 X | |||
| Revenue | 229.83 M | |||
| Gross Profit | 213.39 M | |||
| EBITDA | 104.08 M | |||
| Net Income | 92.86 M | |||
| Cash And Equivalents | 42.72 M | |||
| Cash Per Share | 0.19 X | |||
| Total Debt | 33.39 M | |||
| Current Ratio | 0.94 X | |||
| Book Value Per Share | 9.88 X | |||
| Cash Flow From Operations | 25.68 M | |||
| Earnings Per Share | 4.64 X | |||
| Target Price | 76.34 | |||
| Number Of Employees | 477 | |||
| Beta | 0.12 | |||
| Market Capitalization | 1.09 B | |||
| Total Asset | 368.39 M | |||
| Z Score | 19.2 | |||
| Annual Yield | 0.01 % | |||
| Net Asset | 368.39 M | |||
| Last Dividend Paid | 0.65 |
About Pharma Mar Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pharma Mar SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pharma Mar using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pharma Mar SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Pharma Stock
Pharma Mar financial ratios help investors to determine whether Pharma Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Pharma with respect to the benefits of owning Pharma Mar security.